DPP9 and liver cancer: This study reveals that DPP9 inhibits ubiquitin-mediated degradation of NRF2 protein by binding to KEAP1, up-regulates NRF2 protein levels, promotes mRNA transcription of NQO1, inhibits intracellular ROS levels, and thus weakens the responses of liver cancer to chemotherapy drugs (Fig. 8).